<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095589</url>
  </required_header>
  <id_info>
    <org_study_id>J0382</org_study_id>
    <secondary_id>U01CA084968</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>03-12-30-05</secondary_id>
    <secondary_id>CDR0000401496</secondary_id>
    <nct_id>NCT00095589</nct_id>
    <nct_alias>NCT00185627</nct_alias>
  </id_info>
  <brief_title>Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer</brief_title>
  <official_title>Detection of Bladder Cancer by Microsatellite Analysis (MSA) of Urinary Sediment: Multi-Institutional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: New diagnostic procedures such as microsatellite analysis of sediment in the urine
      may improve the ability to detect bladder cancer without invasive procedures.

      PURPOSE: Diagnostic trial to study the effectiveness of microsatellite analysis of sediment
      in the urine in detecting bladder cancer in healthy participants, participants who have
      genitourinary conditions requiring cystoscopy, and patients who have bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the sensitivity and specificity of microsatellite analysis (MSA) of urine
           sediment with cystoscopy and urine cytology for detecting bladder cancer in participants
           undergoing cystoscopy.

      Secondary

        -  Determine the temporal performance characteristics of MSA in urine sediment from these
           participants.

        -  Determine which of the 15 individual markers or combination of markers that make up the
           MSA test are most predictive of the presence of bladder cancer in these participants.

      OUTLINE: This is a single-blind, multicenter, cohort study.

      Urine and blood specimens are collected from all participants at baseline. Urine specimens
      are examined using microsatellite analysis, urine cytology, and urinalysis. Patients in
      groups 2 and 3 also undergo cystoscopy at baseline.

      Patients in group 3 undergo cystoscopy, upper tract imaging (e.g., abdominal CT scan),
      microsatellite analysis, urine cytology, and urinalysis every 3 months for 2 years in the
      absence of progressive disease.

      Microsatellite analysis, which identifies loss of heterozygosity using polymerase chain
      reaction technique, is conducted for 15 markers: D4S243, D21S1245, FGA, D17S695, D16S476,
      D9S171, IFN-A, D20S48, D13S802, D17S654, D16S310, THO1, D9S162, D9S747, and MBP.

      PROJECTED ACCRUAL: A total of 500 participants (100 each for groups 1 and 2 and 300 for group
      3) will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Actual">125</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>loss of heterozygosity analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microsatellite instability analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cystoscopy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Group 1 (healthy volunteers):

               -  No prior or concurrent urologic disease or devices

               -  No genitourinary (GU) complaints, including urgency or frequency of urination

               -  Normal urinalysis and urine cytology

               -  Never smoked cigarettes regularly (i.e., ≥ 1 cigarette/day for ≥ 1 year)

               -  No suspected exposure to environmental bladder carcinogens for &gt; 1 year,
                  including, but not limited to, the following occupations or exposures:

                    -  Aluminum industry

                    -  Aromatic amines

                    -  Coal gasification

                    -  Coal tars and pitches

                    -  Coke plant

                    -  Dye industry

                    -  Leather industry

                    -  Machinist

                    -  Painter

                    -  Rubber industry

                    -  Truck, bus, or taxi drivers

          -  Group 2 (participants with condition(s) that lead to false-positive urinary bladder
             cancer screening studies):

               -  GU complaints requiring cystoscopy

               -  No current GU malignancy

               -  At least 1 of the following conditions:

                    -  Benign prostatic hypertrophy (International Prostate Symptom Score &gt; 12)

                    -  Foreign bodies (stones, stents, or catheters)

                    -  Hematuria (gross or microscopic)

                    -  GU infection (e.g., prostatitis, urinary tract infection, pyelonephritis,
                       urethritis) within the past 3 months and completed treatment

                         -  No sign of infection at the time of study participation

          -  Group 3 (superficial bladder cancer patients):

               -  Histologically confirmed superficial bladder urothelial malignancy

                    -  Primary or recurrent disease

               -  No nontransitional cell carcinoma of the bladder, upper tract tumors,
                  muscle-invasive tumors, or superficial disease for which local therapy is not
                  appropriate

        PATIENT CHARACTERISTICS:

        Age

          -  Over 40

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  See Disease Characteristics

        Other

          -  No prior cancer except nonmelanoma dermatologic malignancy

               -  Prior bladder cancer allowed for group 3 patients

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

               -  Prior intravesical therapy for bladder cancer allowed for group 3 patients

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark P. Schoenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Strand Urology, LLP</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dan L. Duncan Cancer Center at Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmond Odette Cancer Centre at Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 5, 2004</study_first_submitted>
  <study_first_submitted_qc>November 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2004</study_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

